WO2014160177A3 - Inhibiteurs quinazolines de pi3k - Google Patents

Inhibiteurs quinazolines de pi3k Download PDF

Info

Publication number
WO2014160177A3
WO2014160177A3 PCT/US2014/025980 US2014025980W WO2014160177A3 WO 2014160177 A3 WO2014160177 A3 WO 2014160177A3 US 2014025980 W US2014025980 W US 2014025980W WO 2014160177 A3 WO2014160177 A3 WO 2014160177A3
Authority
WO
WIPO (PCT)
Prior art keywords
pi3k
quinazoline inhibitors
quinazoline
inhibitors
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/025980
Other languages
English (en)
Other versions
WO2014160177A2 (fr
Inventor
Kenneth D. Rice
Paul Foster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of WO2014160177A2 publication Critical patent/WO2014160177A2/fr
Publication of WO2014160177A3 publication Critical patent/WO2014160177A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (I) : et des sels pharmaceutiquement acceptables, ainsi que des procédés de fabrication et d'utilisation des composés pour inhiber PI3K.
PCT/US2014/025980 2013-03-13 2014-03-13 Inhibiteurs quinazolines de pi3k Ceased WO2014160177A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779679P 2013-03-13 2013-03-13
US61/779,679 2013-03-13

Publications (2)

Publication Number Publication Date
WO2014160177A2 WO2014160177A2 (fr) 2014-10-02
WO2014160177A3 true WO2014160177A3 (fr) 2015-05-14

Family

ID=50625117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/025980 Ceased WO2014160177A2 (fr) 2013-03-13 2014-03-13 Inhibiteurs quinazolines de pi3k

Country Status (1)

Country Link
WO (1) WO2014160177A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018325445A1 (en) * 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
PH12021552759A1 (en) * 2019-04-30 2022-07-04 Abbvie Inc Substituted cycloalkyls as modulators of the integrated stress pathway
CN114423759B (zh) * 2019-10-25 2023-10-20 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
MX2024003363A (es) * 2021-09-22 2024-04-04 Sichuan Huiyu Pharmaceutical Co Ltd Derivado de piridina y uso del mismo.
CN118043044A (zh) * 2021-09-30 2024-05-14 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
CN118632843A (zh) * 2022-03-03 2024-09-10 四川汇宇制药股份有限公司 一种吡啶类衍生物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2585909A (en) * 1948-11-05 1952-02-19 Muriel Ruth Curd Quaternary salts of pyrimidylaminoquinolines
WO2008009078A2 (fr) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
WO2009155121A2 (fr) * 2008-05-30 2009-12-23 Amgen Inc. Inhibiteurs de la pi3 kinase
WO2010151737A2 (fr) * 2009-06-25 2010-12-29 Amgen Inc. Composés hétérocycliques et leurs utilisations
WO2011022439A1 (fr) * 2009-08-17 2011-02-24 Intellikine, Inc. Composés hétérocycliques et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2585909A (en) * 1948-11-05 1952-02-19 Muriel Ruth Curd Quaternary salts of pyrimidylaminoquinolines
WO2008009078A2 (fr) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
WO2009155121A2 (fr) * 2008-05-30 2009-12-23 Amgen Inc. Inhibiteurs de la pi3 kinase
WO2010151737A2 (fr) * 2009-06-25 2010-12-29 Amgen Inc. Composés hétérocycliques et leurs utilisations
WO2011022439A1 (fr) * 2009-08-17 2011-02-24 Intellikine, Inc. Composés hétérocycliques et leurs utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANDREAS SCHMIDT ET AL: "Functionalized 4-Aminoquinolines by Rearrangement of Pyrazole N-Heterocyclic Carbenes", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 49, no. 15, 12 March 2010 (2010-03-12), pages 2790 - 2793, XP055119383, ISSN: 1433-7851, DOI: 10.1002/anie.200905436 *
ANDREW S ROSENTHAL ET AL: "Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 10, 28 February 2011 (2011-02-28), pages 3152 - 3158, XP028208799, ISSN: 0960-894X, [retrieved on 20110304], DOI: 10.1016/J.BMCL.2011.02.114 *
DAVIS S E ET AL: "2,4-DIAMINO-5-BENZYLPYRIMIDINES AND ANALOGUES AS ANTIBACTERIAL AGENTS. 11. QUINOLYLMETHYL ANALOGUES WITH BASIC SUBSTITUENTS CONVEYING SPECIFICITY", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 32, 1 January 1989 (1989-01-01), pages 1936 - 1942, XP002273433, ISSN: 0022-2623, DOI: 10.1021/JM00128A041 *
GEMMA ET AL: "Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives", TETRAHEDRON LETTERS, PERGAMON, GB, vol. 49, no. 13, 2 February 2008 (2008-02-02), pages 2074 - 2077, XP022502902, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2008.01.128 *
SIVARAMAKRISHNAN K P ET AL: "Biquinoline Series: Part III - Synthesis of Substituted 6,6'-Biuinolines", JOURNAL OF SCIENTIFIC AND INDUSTRIAL RESEARCH. SERIE B: PHYSICALSCIENCES, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DEHLI, IN, vol. 20, 1 January 1961 (1961-01-01), pages 223 - 227, XP009178121, ISSN: 0368-4210 *
TOBE M ET AL: "A novel structural class of potent inhibitors of NF-kappaB activation: structure-activity relationship and biological effects of 6-aminoquinazoline derivatives", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 11, no. 18, 1 January 2003 (2003-01-01), pages 3869 - 3878, XP003024664, ISSN: 0968-0896, DOI: 10.1016/S0968-0896(03)00438-3 *
YVONNICK LOIDREAU ET AL: "Microwave-assisted thermal decomposition of formamide: a tool for coupling a pyrimidine ring with an aromatic partner", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 67, no. 26, 3 May 2011 (2011-05-03), pages 4852 - 4857, XP028227650, ISSN: 0040-4020, [retrieved on 20110517], DOI: 10.1016/J.TET.2011.05.010 *

Also Published As

Publication number Publication date
WO2014160177A2 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
PH12015502284A1 (en) Protein kinase inhibitors
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
CA2875877C (fr) Inhibiteurs syk
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
EA201490759A1 (ru) Ингибиторы протеинкиназы
HK1220355A1 (zh) Mk2抑制劑和其用途
JO3317B1 (ar) مركبات تترا هيدروبيرولو ثيازين
NZ715747A (en) Syk inhibitors
PH12021552233A1 (en) USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
WO2014028597A3 (fr) Composés indazole et indole à substitution cyclohexyl et 3-cyclohexenyl
PH12015501755A1 (en) Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2012071509A3 (fr) Benzoxazépines utilisées comme inhibiteurs de p13k/mtor et procédés d'utilisation et de fabrication
CA2929436C (fr) Composes, composition pharmaceutique et methodes a utiliser dans le traitement de maladies inflammatoires
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201600434A1 (ru) Применение производных бензимидазолпролина
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201500930A1 (ru) Новые ингибиторы
EA201500931A1 (ru) Производные пиридин-4-ила
JO3318B1 (ar) مثبطات bace
WO2012074869A8 (fr) Benzoxazépines en tant qu'inhibiteurs de pi3k/mtor, et leurs procédés d'utilisation et de fabrication
MY184561A (en) Substituted pyrimidine compounds and their use as syk inhibitors
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14720345

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14720345

Country of ref document: EP

Kind code of ref document: A2